ChemoID test leads to better outcomes in platinum-resistant ovarian cancer
MSN highlights research published in npj Precision Oncology
MSN and MSN UK highlighted results from a new Phase 3 trial published in the journal npj Precision Oncology that found a cancer stem cell test can accurately choose more effective treatments and lead to improved outcomes for patients with platinum-resistant ovarian cancer.
The University of Cincinnati Cancer Center’s Thomas Herzog, MD, the study’s first author, said epithelial ovarian cancer often initially responds to chemotherapy treatment and then enters a period of resistance to therapy and tumor regrowth.
“This is partly due to the selection and reactivation of cancer stem cells (CSCs) that rebuild and repair the tumor from the damage received from chemotherapy,” said Herzog, a Cancer Center physician researcher, the Paul and Carolyn Flory Professor in Gynecologic Oncology in the UC College of Medicine and director of UC Health’s Gynecologic Cancer Disease Center.
Pier Paolo Claudio, MD, who codeveloped the clinical test, said the ChemoID platform challenges the CSCs found in individual patients' tumors against specific anticancer drugs to identify which drugs are likely to be the most effective.
The 81 patients with platinum-resistant ovarian cancer (cancer recurrence within six months of receiving a platinum-based chemotherapy) enrolled in the trial were randomized to have the choice of chemotherapy treatment decided through ChemoID or to have physicians choose using standard methods. Herzog said doctors selecting treatments typically rely on approved therapies, past experiences, patients’ prior treatments, and toxicity or side effects patients have already experienced.
The overall response rate of patients in the ChemoID arm was 50%, compared to 5% for patients in the physician-choice arm. Median progression free survival for patients in the ChemoID arm was 11 months, compared to a median of three months for the physician-choice arm. ChemoID patients had a median duration of response of eight months, compared to five-and-a-half months for physician-choice.
Featured photo at top of ovarian cancer cells. Photo/OGPhoto/iStock.
Related Stories
Simple ways to find a deeper sense of happiness and well being
October 8, 2026
UC assistant professor Suzie White, featured in an AARP story on practical ways to live a happier, healthier life, shared research-backed strategies for increasing well-being through gratitude and service to others. White teaches Happiness in Action, a course that helps students apply the science of happiness in everyday life.
New vending machine helps people with addiction
October 8, 2026
The University of Cincinnati's Daniel Arendt was featured in a Spectrum News report on a new harm reduction vending machine installed at the IPM Food Pantry in partnership with the Hamilton County Mental Health and Recovery Services Board.
UC study correlates increased physical activity with slower Parkinson’s progression
October 7, 2026
Higher levels of physical activity were associated with slower declines in thinking and memory as well as slower worsening of movement symptoms for people with Parkinson’s disease, according to a new study led by University of Cincinnati researchers published Oct. 7, 2026, in Neurology.